FDA Approvals, News & UpdatesLymphomaNewsworthy

Polivy a New Targeted Immunotherapy Approved for Patients with B-Cell Lymphoma

In June 2019, the FDA approved a new type of immunotherapy called Polivy, for use in combination with other drugs, in patients with previously treated diffuse large B-cell lymphoma (DLBCL), offering new options for patients whose cancer has returned.
August 2019 Vol 5 No 4

In June 2019, the FDA approved Polivy (polatuz­umab vedotin-piiq; from Genentech), a new targeted immunotherapy called CD79b-directed antibody–drug conjugate, in combination with the immunotherapy Rituxan (rituximab; from Genentech; or a biosimilar of Rituxan) plus the chemotherapy bendamustine, for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after 2 or more therapies.

“Antibody-drug conjugates are an emerging class of targeted immunotherapies for cancer. This type of therapy, unlike traditional chemotherapy, is intended to target specific cells,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence. “Today’s approval of Polivy provides an alternative option for patients in whom multiple treatments have not worked.”

The FDA approved Polivy based on a clinical trial showing that in patients with relapsed or refractory DLBCL who received Polivy plus the chemoimmunotherapy combination, the tumor responded much better than in patients who received chemotherapy plus Rituxan but without Polivy. In fact, some of those patients had no signs of lymphoma for 12 months or longer.

The most common side effects with Polivy were low white blood cells, anemia, peripheral neuropathy, fatigue, diarrhea, fever, low appetite, and pneumonia.

Recommended For You
Breast CancerFDA Approvals, News & Updates
Trodelvy New Therapy Approved for Triple-Negative Breast Cancer
In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
BiomarkersFDA Approvals, News & Updates
Tabrecta Approved for NSCLC with MET Biomarker

On May 6, 2020, the FDA approved Tabrecta (capmatinib; from Novartis), an oral kinase inhibitor, for adults with metastatic (spreading) non–small-cell lung cancer (NSCLC).

FDA Approvals, News & UpdatesOvarian Cancer
Zejula Now Approved as First-Line Maintenance Therapy in All Patients with Ovarian Cancer

On April 29, 2020, the FDA approved Zejula (niraparib; from GlaxoSmithKline), an oral PARP inhibitor, as the first PARP inhibitor approved for first-line maintenance (long-term) therapy for all patients with advanced ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal cancer) whose cancer had a complete or partial response to platinum-based chemotherapy.

CholangiocarcinomaFDA Approvals, News & Updates
Pemazyre First Therapy Approved for Cholangiocarcinoma with FGFR2 Biomarker
In April, the FDA approved Pemazyre, the first targeted drug for patients with advanced cholangiocarcinoma and a biomarker called FGFR2 gene fusion.
Last modified: September 3, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.